作为肺癌治疗点的 Src 和 Abl:药物重定位的机会
Raquel Ramos1,2,3, Carlos Sousa1,3, Nuno Vale1,2,4
1PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
Pharmaceuticals (Basel, Switzerland)
|October 29, 2025
概括
药物重新定位为癌症治疗提供了一种具有成本效益的策略. 本综述探讨了针对Src和Abl的五种氨酸激酶抑制剂,突出了它们在治疗肺癌和其他疾病方面的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 在癌症治疗中,个性化医疗和向治疗非常重要.
- 药物重新定位是一种有效的策略,利用现有的已批准药物用于新的适应症.
- Src 和 Abl 氨酸激酶是瘤发育,增殖,迁移和血管生成的关键参与者.
研究的目的:
- 审查五种针对Src和/或Abl.的氨酸激酶抑制剂 (萨拉卡提尼布,伊马替尼布,PP2,尼罗丁尼布,蒂尔巴尼布林).
- 讨论它们的作用机制,原始适应症和重用潜力,特别是在肺癌中.
- 突出这些抑制剂在个性化医学中的异质性疾病 (如肺癌) 中的治疗前景.
主要方法:
- 现有临床前和临床研究的综合文献综述.
- 对所选抑制剂的分子标 (Src 和 Abl 氨酸激酶) 的分析.
- 基于疗效和安全数据的药物重用潜力的评估.
主要成果:
- 确定了五种针对Src和/或Abl的铁激酶抑制剂 (萨拉卡提尼布,伊马替尼布,PP2,尼罗丁尼布,提巴尼布林).
- 这些抑制剂显示出超出其原始指示的重新用途的潜力.
- 临床前和临床数据表明,在特定的肺癌亚型中具有有前途的治疗作用.
结论:
- Src 和 Abl 抑制剂在最初的用途之外具有显著的治疗潜力.
- 这些药物可能在未来的肺癌治疗中发挥作用,特别是在个性化医疗方法中.
- 需要进一步的研究,以充分阐明这些重新定位的药物的肺癌疗效和安全性.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:26Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K